CTRI/2022/02/040396Completed未知
A RANDOMISED CONTROLLED TRIAL COMPARING VITAMIN K STATUS INLESS THAN 32WEEKS AND OR LESS THAN 1500GMS AFTER 3 PROPHYLACTIC DOSAGE REGIMENS (0.3VS 0.5 MG VS 1MG IM) AT BIRTH
il0 sites75 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 75
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Preterm neonates less than 32 weeks of gestation and/or less than 1500 g born during the study period
Exclusion Criteria
- •Outborn neonates who already received vitamin K, those with antenatally diagnosed major congenital malformations and intracranial hemorrhage, neonates whose mothers had thrombophilia or platelet disorders, and who received drug treatment with known vitamin K antagonists.
Investigators
Similar Trials
Recruiting
Phase 2
A study to assess the safety of non-vitamin K antagonist oral anticoagulants on high-risk gastrointestinal endoscopic proceduresAll diseases that require high-risk gastrointestinal endoscopic procedures such as endoscopic polypectomy, endoscopic mucosal resection, endoscopic submucosal dissection, endoscopic balloon dilation, endoscopic mucosal ablation or percutaneous endoscopic gastrostomyJPRN-UMIN000018284Osaka International Cancer Institute50
Active, not recruiting
Phase 1
The effect of administering VITamin K preprocedural on the vitamin K dependent coagulation factors and the INR in patients anticoagulated with ACEnocoumarolEUCTR2018-002291-41-NLGelderse Vallei Hospital80
Recruiting
Phase 4
The effect of administering VITamin K preprocedural on the vitamin K dependent coagulation factors and the INR in patients anticoagulated with ACEnocoumarol (VITKACE-study)NL-OMON46375Ziekenhuisvoorzieningen Gelderse Vallei80
Recruiting
Phase 1
Treatment of patients with leukemia using NK cellsIRCT2017083027520N9Stem Cell And Regenerative Medicine Institute10
Completed
Not Applicable
Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosisCystic fibrosisISRCTN14200211Barts and the London NHS Trust (UK)40